1029501
USP
苯磺酸氨氯地平(钙拮抗药)
United States Pharmacopeia (USP) Reference Standard
别名:
苯磺酸氨氯地平, 2-[(2-氨基乙氧基)-甲基]-4-(2-氯苯基)-1,4-二氢-6-甲基-3,5-吡啶二甲酸 3-乙基 5-甲酯苯磺酸酯, 活络喜(抗高血压药)
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H25ClN2O5 · C6H5SO3H
化学文摘社编号:
分子量:
567.05
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
amlodipine
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC
InChI
1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
InChI key
ZPBWCRDSRKPIDG-UHFFFAOYSA-N
基因信息
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
正在寻找类似产品? 访问 产品对比指南
一般描述
本产品按照现行药典要求提供和指定。所有为支持本产品而提供的信息，包括 SDS 和任何产品信息小册子，均由药典颁发机构制定和发布。如需进一步的信息和支持，请访问现行药典网站。如需进一步信息和支持，请访问现行药典网站。
应用
苯磺酸氨氯地平USP参考标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 氨氯地平和阿托伐他汀片
- 氨氯地平和盐酸贝那普利胶囊
- 氨氯地平和奥美沙坦酯片
- 氨氯地平和缬沙坦片
- 氨氯地平苯磺酸盐
- 氨氯地平苯磺酸盐片
- 氨氯地平复方口服混悬液
生化/生理作用
氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物，作用于 Ca V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长，对雄性大鼠有抗生殖作用。
苯磺酸氨氯地平是一种 L 型钙通道阻滞剂。
分析说明
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。
其他说明
可能适用相应的销售限制。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Roy Blank
Drugs of today (Barcelona, Spain : 1998), 42(3), 157-175 (2006-04-22)
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood pressure-lowering agent with pleiotropic effects, and atorvastatin calcium, a statin with lipid-lowering as well as pleiotropic
J M Krzesinski et al.
Revue medicale de Liege, 62(11), 688-694 (2008-01-26)
Hypertension is a common treatable risk factor for cardiovascular disease. Even when identified and treated, most patients with hypertension do not get to blood pressure goal and they often need at least two antihypertensive agents to achieve blood pressure control.
S Hadžidedić et al.
Pharmaceutical development and technology, 19(8), 930-941 (2013-10-09)
The aim of this study was to compare the specific characteristics of the S-enantiomer and the racemate of amlodipine besylate (AB) in order to design a robust and stable formulation of the active S-enantiomer which will guarantee continuous performance of
Roy Blank et al.
Drugs of today (Barcelona, Spain : 1998), 43(3), 157-177 (2007-03-24)
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering agent, and atorvastatin calcium, a statin with lipid-lowering antiatherosclerotic properties. Amlodipine and atorvastatin have been demonstrated
Abdel Naser Zaid et al.
Pakistan journal of pharmaceutical sciences, 27(4), 755-762 (2014-07-13)
The aim of this study was to formulate a film-coated Valsartan/Amlodipine (VS/AM) immediate release tablets and to evaluate their in vivo release profile. VS/AM core tablets were manufactured using dry granulation method. Opadry aqueous coating dispersion was used as film
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持